Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study
Open Access
- 1 January 2023
- journal article
- research article
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 82
Abstract
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant predominance in Serbia. Methods. The data for the period from Aug 18th to Oct 1st 2021, were used to estimate the incidence rates of the SARS-CoV-2 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission. The study included 41,186 fully vaccinated subjects, of which 13,589 had received the third dose. VE was estimated based on the incidence rate ratio following vaccination with three versus two doses. Results. We found that a third dose of all investigated vaccines reduces the incidence of both SARS-CoV-2 infection and severe illness that requires hospitalization or ICU admission. The highest VE against infection demonstrated BNT162b2, followed by Gam-COVID-Vac and BBIBP-CorV. Third dose vaccination reduced the risk of hospitalization (incidence rate IR = 0 for Gam-COVID-Vac and BBIBP-CorV), and ICU admission (IR = 0 for all vaccines). The hazard distributions for SARS-CoV-2 infection and hospitalization following vaccination with three versus two doses were significantly different. Conclusion. These findings indicate that an additional, third dose of studied vaccine boosters protection against all investigated outcomes.Keywords
This publication has 27 references indexed in Scilit:
- Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohortVaccine, 2023
- Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccineClinical and Translational Medicine, 2022
- Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort studyThe Lancet Regional Health - Americas, 2022
- Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adultsFrontiers of Medicine, 2022
- Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in IsraelJAMA, 2022
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyThe Lancet, 2021
- Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reachVaccine, 2021
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)The Lancet, 2021
- Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policyVaccine, 2014